Your browser doesn't support javascript.
loading
Challenges in Permeability Assessment for Oral Drug Product Development.
Koziolek, Mirko; Augustijns, Patrick; Berger, Constantin; Cristofoletti, Rodrigo; Dahlgren, David; Keemink, Janneke; Matsson, Pär; McCartney, Fiona; Metzger, Marco; Mezler, Mario; Niessen, Janis; Polli, James E; Vertzoni, Maria; Weitschies, Werner; Dressman, Jennifer.
Afiliación
  • Koziolek M; NCE Drug Product Development, Development Sciences, AbbVie Deutschland GmbH & Co. KG, 67061 Ludwigshafen, Germany.
  • Augustijns P; Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.
  • Berger C; Chair of Tissue Engineering and Regenerative Medicine, University Hospital Würzburg, 97070 Würzburg, Germany.
  • Cristofoletti R; Department of Pharmaceutics, University of Florida, 6550 Sanger Road, Orlando, FL 32827, USA.
  • Dahlgren D; Department of Pharmaceutical Biosciences, Uppsala University, 75124 Uppsala, Sweden.
  • Keemink J; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, 4070 Basel, Switzerland.
  • Matsson P; Department of Pharmacology and SciLifeLab Gothenburg, University of Gothenburg, 40530 Gothenburg, Sweden.
  • McCartney F; School of Veterinary Medicine, University College Dublin, D04 V1W8 Dublin, Ireland.
  • Metzger M; Translational Center for Regenerative Therapies (TLZ-RT) Würzburg, Branch of the Fraunhofer Institute for Silicate Research (ISC), 97082 Würzburg, Germany.
  • Mezler M; Quantitative, Translational & ADME Sciences, AbbVie Deutschland GmbH & Co. KG, 67061 Ludwigshafen, Germany.
  • Niessen J; Department of Pharmaceutical Biosciences, Uppsala University, 75124 Uppsala, Sweden.
  • Polli JE; Department of Pharmaceutical Sciences, University of Maryland, Baltimore, MD 21021, USA.
  • Vertzoni M; Department of Pharmacy, National and Kapodistrian University of Athens, 157 84 Zografou, Greece.
  • Weitschies W; Institute of Pharmacy, University of Greifswald, 17489 Greifswald, Germany.
  • Dressman J; Fraunhofer Institute of Translational Medicine and Pharmacology, 60596 Frankfurt, Germany.
Pharmaceutics ; 15(10)2023 Sep 28.
Article en En | MEDLINE | ID: mdl-37896157
ABSTRACT
Drug permeation across the intestinal epithelium is a prerequisite for successful oral drug delivery. The increased interest in oral administration of peptides, as well as poorly soluble and poorly permeable compounds such as drugs for targeted protein degradation, have made permeability a key parameter in oral drug product development. This review describes the various in vitro, in silico and in vivo methodologies that are applied to determine drug permeability in the human gastrointestinal tract and identifies how they are applied in the different stages of drug development. The various methods used to predict, estimate or measure permeability values, ranging from in silico and in vitro methods all the way to studies in animals and humans, are discussed with regard to their advantages, limitations and applications. A special focus is put on novel techniques such as computational approaches, gut-on-chip models and human tissue-based models, where significant progress has been made in the last few years. In addition, the impact of permeability estimations on PK predictions in PBPK modeling, the degree to which excipients can affect drug permeability in clinical studies and the requirements for colonic drug absorption are addressed.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Pharmaceutics Año: 2023 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Pharmaceutics Año: 2023 Tipo del documento: Article País de afiliación: Alemania